Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -2082.59% is 53% below its 5-year average of -1357.00%, around the middle of its 5-year range (-6227.12%–-41.37%).
8.85% below its 12-month average of -1913.31%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -1361.86%.
EBITDA MARGIN
-2082.59%
EBITDA MARGIN AVG TTM
-1913.31%
EBITDA MARGIN AVG 3Y
-2171.31%
EBITDA MARGIN AVG 5Y
-1357.00%
EBITDA MARGIN AVG 10Y
-1145.29%
EBITDA MARGIN AVG 15Y
-1100.61%
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-8.85%
CURRENT VS 3Y AVG
+4.09%
CURRENT VS 5Y AVG
-53.47%
CURRENT VS 10Y AVG
-81.84%
CURRENT VS 15Y AVG
-89.22%
CURRENT VS 20Y AVG
N/A
Fate Therapeutics, Inc.
Market Cap
$272.17M
EBITDA Margin
-2082.59%
TTM Avg
-1913.31%
3Y Avg
-2171.31%
5Y Avg
-1357.00%
Market Cap
$272.91M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$275.95M
EBITDA Margin
-13.37%
TTM Avg
-2.68%
3Y Avg
-19.85%
5Y Avg
-36.16%
Market Cap
$279.56M
EBITDA Margin
-1475.69%
TTM Avg
-1475.69%
3Y Avg
-2002.71%
5Y Avg
-1922.41%
Market Cap
$281.16M
EBITDA Margin
-25.38%
TTM Avg
-1946.60%
3Y Avg
-1509.96%
5Y Avg
-1364.90%
Market Cap
$258.34M
EBITDA Margin
-7643.91%
TTM Avg
-11162.31%
3Y Avg
-5581.16%
5Y Avg
-3720.77%
Market Cap
$259.30M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$286.94M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$258.48M
EBITDA Margin
-768.62%
TTM Avg
-551.06%
3Y Avg
-374.75%
5Y Avg
-290.29%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Fate Therapeutics, Inc. (FATE) | $272.17M | -2082.59% | -1913.31% | -2171.31% | -1357.00% |
| Indaptus Therapeutics, Inc. (INDP)vs › | $272.91M | N/A | N/A | N/A | N/A |
| Aurora Cannabis Inc. (ACB)vs › | $275.95M | -13.37% | -2.68% | -19.85% | -36.16% |
| Abeona Therapeutics Inc. (ABEO)vs › | $279.56M | -1475.69% | -1475.69% | -2002.71% | -1922.41% |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $281.16M | -25.38% | -1946.60% | -1509.96% | -1364.90% |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $258.34M | -7643.91% | -11162.31% | -5581.16% | -3720.77% |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $259.30M | N/A | N/A | N/A | N/A |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $286.94M | N/A | N/A | N/A | N/A |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $258.48M | -768.62% | -551.06% | -374.75% | -290.29% |
| AC Immune S.A. (ACIU)vs › | $258.00M | -1857.26% | -1020.57% | -1032.24% | -903.20% |
Gross Margin
-94.1%
EBITDA Margin
-2082.6%
Operating Margin
-2222.4%
Net Margin
-1941.1%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -1361.86% |
| 2026-03-31 | -2315.78% |
| 2025-12-31 | -2312.49% |
| 2025-09-30 | -1809.76% |
| 2025-06-30 | -1766.65% |
| 2025-03-31 | -2329.47% |
| 2024-12-31 | -3061.02% |
| 2024-09-30 | -1554.00% |
| 2024-06-30 | -596.01% |
| 2024-03-31 | -2402.44% |
| 2023-12-31 | -2576.97% |
| 2023-09-30 | -2393.98% |
| 2023-06-30 | -6227.12% |
| 2023-03-31 | -41.37% |
| 2022-12-31 | -134.32% |
| 2022-09-30 | -555.36% |
| 2022-06-30 | -432.08% |
| 2022-03-31 | -389.41% |
| 2021-12-31 | -393.56% |
| 2021-09-30 | -373.31% |
| 2021-06-30 | -340.09% |
| 2021-03-31 | -406.13% |
| 2020-12-31 | -204.69% |
| 2020-09-30 | -406.38% |
| 2020-06-30 | -511.60% |
| 2020-03-31 | -1343.42% |
| 2019-12-31 | -1015.52% |
| 2019-09-30 | -1092.30% |
| 2019-06-30 | -835.68% |
| 2019-03-31 | -760.11% |
| 2018-12-31 | -988.20% |
| 2018-09-30 | -1596.69% |
| 2018-06-30 | -1881.60% |
| 2018-03-31 | -1341.91% |
| 2017-12-31 | -1163.97% |
| 2017-09-30 | -984.02% |
| 2017-06-30 | -910.23% |
| 2017-03-31 | -950.83% |
| 2016-12-31 | -725.51% |
| 2016-09-30 | -796.39% |
| 2016-06-30 | -756.67% |
| 2016-03-31 | -581.62% |
| 2015-12-31 | -622.86% |
| 2015-09-30 | -598.54% |
| 2015-06-30 | -2144.68% |
| 2013-12-31 | 491.56% |
| 2013-09-30 | -2396.17% |
| 2013-06-30 | -1422.07% |
| 2013-03-31 | -677.75% |
| 2012-12-31 | -604.04% |
| 2012-09-30 | -662.31% |
